Different particulate systems - Bypass the biological barriers

Journal of Drug Targeting

Volumn 18, Issue 4, 2010, Pages 243-253

  Jǎtariu, Anca N ^a   Popa, Marcel ^a   Peptu, Cǎtǎlina A ^a  

^a GHEORGHE ASACHI TECHNICAL UNIVERSITY OF IASI   (Romania)

Author keywords

Biological barriers; Liposomes; Nanoparticles; Solid lipid nanoparticles

Indexed keywords

LIPOSOME; NANOPARTICLE; SOLID LIPID NANOPARTICLE;

BLOOD BRAIN BARRIER; DRUG DELIVERY SYSTEM; EYE; HUMAN; MEMBRANE VESICLE; MICROEMULSION; MULTILAMELLAR VESICLE; PRIORITY JOURNAL; REVIEW; SKIN; SMALL UNILAMELLAR VESICLE; TUMOR;

BLOOD-AQUEOUS BARRIER; BLOOD-BRAIN BARRIER; DRUG CARRIERS; HUMANS; LIPIDS; NANOPARTICLES; SKIN;

EID: 77951118950     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/10611860903398099     Document Type: Review

References (84)

1. Abbott NJ. (2002). Astrocyte-endothelial interactions and blood-brain barrier permeability. J Anat, 200: 629-638.
2. Abdelwahed W, Degobert G, Stainmesse S, Fessi H. (2006). Freezedrying of nanoparticles: formulation, process and storage considerations. Adv Drug Deliv Rev, 58(15): 1688-1713.
3. Afergan E, Epstein H, Dahan R, Koroukhov N, Rohekar K, Danenberg HD, Golomb G. (2008). Delivery of serotonin to the brain by monocytes following phagocytosis of liposomes. J Control Release, 132: 84-90. 10.1016/j.jconrel. 2008.08.017.
4. Ajit PR, Sunil AA, Sangamesh AP, Nadagouda NM, Padmakar VK and Tejraj MA. (2006). Semi-interpenetrating polymer network microspheres of gelatin and sodium carboxymethyl cellulose for controlled release of ketorolac tromethamine. Carbohydr Polym, 65(3): 243-252.
5. Alonso MJ, Sánchez A. (2003). The potential of chitosan in ocular drug delivery. J Pharm Pharmacol, 55: 1451-1463. 10.1211/0022357022476. (Pubitemid 37441350)
6. Ambruosi A, Gelperina S, Khalansky A, Tanski S, Theisen A, Kreuter J. (2006). Influence of surfactants, polymer and doxorubicin loading on the anti-tumour effect of poly(butyl cyanoacrylate) nanoparticles in a rat glioma model. J Microencapsul, 23: 582-592. 10.1080/02652040600788080. (Pubitemid 44446597)
7. Amiji MM. (2007). Nanotechnology for Cancer Therapy. CRC Press, New York.
8. Attama AA, Reichl S, Müller-Goymann CC. (2008). Diclofenac sodium delivery to the eye: in vitro evaluation of novel solid lipid nanoparticle formulation using human cornea construct. Int J Pharm, 355: 307-313. 10.1016/j.ijpharm.2007.12.007.
9. Basu SC, Basu M. (2002). Liposome Methods and Protocols. Methods in Molecular Biology. Humana Press, New York.
10. Bazzo GC, Lemos-Senna E, Pires ATN. (2008). Poly(3-hydroxybutyrate)/ chitosan/ketoprofen or piroxicam composite microparticles: Preparation and controlled drug release evaluation. Carbohydr Polym, 77(4): 839-844.
11. Beck RC, Pohlmann AR, Hoffmeister C, Gallas MR, Collnot E, Schaefer UF, Guterres SS, Lehr CM. (2007). Dexamethasoneloaded nanoparticle-coated microparticles: correlation between in vitro drug release and drug transport across Caco-2 cell monolayers. Eur J Pharm Biopharm, 67(1): 18-30. 10.1016/j. ejpb.2007.01.007.
12. Berg ES, Skaug K. (2003). Liposome encapsulation of the internal control for whole process quality assurance of nucleic acid amplification-based assays. J Microbiol Methods, 55(1): 303-309.
13. Bhaskar K, Anbu J, Ravichandiran V, Venkateswarlu V, Rao YM. (2009). Lipid nanoparticles for transdermal delivery of flurbiprofen: formulation, in vitro, ex vivo and in vivo studies. Lipids Health Dis, 8: 6. 10.1186/1476-511X-8-16
14. Bhumkar DR, Pokharkar VB. (2006). Studies on effect of pH on crosslinking of chitosan with sodium tripolyphosphate: A technical note. AAPS PharmSciTech, 7(2): E138-E143.
15. Blasi P, Giovagnoli S, Schoubben A, Ricci M, Rossi C. (2007). Solid lipid nanoparticles for targeted brain drug delivery. Adv Drug Deliv Rev, 59: 454-477. 10.1016/j.addr.2007.04.011. (Pubitemid 47259226)
16. Brioschi A, Zara GP, Calderoni S, Gasco MR, Mauro A. (2008). Cholesterylbutyrate solid lipid nanoparticles as a butyric acid prodrug. Molecules, 13: 230-254.
17. Brioschi A, Zenga F, Zara GP, Gasco MR, Ducati A, Mauro A. (2007). Solid lipid nanoparticles: could they help to improve the efficacy of pharmacologic treatments for brain tumors? Neurol Res, 29: 324-330. 10.1179/016164107X187017. (Pubitemid 46802372)
18. Bruschi ML, Cardoso ML, Lucchesi MB, Gremião MP. (2003). Gelatin microparticles containing propolis obtained by spray-drying technique: preparation and characterization. Int J Pharm, 264(1-2): 45-55.
19. Calvo P, Vila-Jato JL, Alonso MJ. (1997). Evaluation of cationic polymer-coated nanocapsules as ocular drug carriers. Int J Pharm, 153(1): 41-50. (Pubitemid 27283332)
20. Cevc G. (2004). Lipid vesicles and other colloids as drug carriers on the skin. Adv Drug Deliv Rev, 56: 675-711. 10.1016/j. addr.2003.10.028.
21. Cortesi R, Argnani R, Esposito E, Dalpiaz A, Scatturin A, Bortolotti F, Lufino M, Guerrini R, Cavicchioni G, Incorvaia C, Menegatti E, Manservigi R. (2006). Cationic liposomes as potential carriers for ocular administration of peptides with anti-herpetic activity. Int J Pharm, 317: 90-100. 10.1016/j.ijpharm.2006.02.050. (Pubitemid 43866344)
22. Diebold Y, Jarrín M, Sáez V, Carvalho EL, Orea M, Calonge M, Seijo B, Alonso MJ. (2007). Ocular drug delivery by liposome-chitosan nanoparticle complexes (LCS-NP). Biomaterials, 28: 1553-1564. 10.1016/j.biomaterials.2006.11.028. (Pubitemid 46027250)
23. Dubey V, Mishra D, Dutta T, Nahar M, Saraf DK, Jain NK. (2007). Dermal and transdermal delivery of an anti-psoriatic agent via ethanolic liposomes. J Control Release, 123: 148-154. 10.1016/j. jconrel.2007.08.005.
24. Ercelen S, Zhang X, Duportail G, Grandfils C, Desbrières J, Karaeva S, Tikhonov V, Mély Y, Babak V. (2006). Physicochemical properties of low molecular weight alkylated chitosans: a new class of potential nonviral vectors for gene delivery. Colloids Surf B Biointerfaces, 51: 140-148. 10.1016/j.colsurfb.2006.06.008. (Pubitemid 44251280)
25. Erdem M, Yüksel E, Tay T, Cimen Y, Türk H. (2009). Synthesis of novel methacrylate based adsorbents and their sorptive properties towards p-nitrophenol from aqueous solutions. J Colloid Interface Sci, 333(1): 40-48. 10.1016/j.jcis.2009.01.014.
26. Esposito E, Fantin M, Marti M, Drechsler M, Paccamiccio L, Mariani P, Sivieri E, Lain F, Menegatti E, Morari M, Cortesi R. (2008). Solid lipid nanoparticles as delivery systems for bromocriptine. Pharm Res, 25: 1521-1530. 10.1007/s11095-007-9514-y.
27. Fang JY. (2006). Nano-or submicron-sized liposomes as carriers for drug delivery. Chang Gung Med J, 29: 358-362.
28. Fetterly GJ, Straubinger RM. (2003). Pharmacokinetics of paclitaxelcontaining liposomes in rats. AAPS PharmSci, 5: 90-100. 10.1208/ ps050432.
29. Garcia-Garcia E, Andrieux K, Gil S, Couvreur P. (2005). Colloidal carriers and blood-brain barrier (BBB) translocation: a way to deliver drugs to the brain? Int J Pharm, 298: 274-292. 10.1016/j. ijpharm.2005.03.031.
30. Garg A, Tisdale AW, Haidari E, Kokkoli E. (2009). Targeting colon cancer cells using PEGylated liposomes modified with a fibronectin-mimetic peptide. Int J Pharm, 366: 201-210. 10.1016/j. ijpharm.2008.09.016.
31. Gaudana R, Jwala J, Boddu SH, Mitra AK. (2009). Recent perspectives in ocular drug delivery. Pharm Res, 26: 1197-1216. 10.1007/ s11095-008-9694-9700
32. Gavini E, Chetoni P, Cossu M, Alvarez MG, Saettone MF, Giunchedi P. (2004). PLGA microspheres for the ocular delivery of a peptide drug, vancomycin using emulsification/spray-drying as the preparation method: in vitro/in vivo studies. Eur J Pharm Biopharm, 57: 207-212. 10.1016/j.ejpb.2003.10.018. (Pubitemid 38283696)
33. Grant SA. (2002). The Holy Grail: long-acting local anaesthetics and liposomes. Best Pract Res Clin Anaesthesiol, 16(2): 345-352.
34. Gregoriadis G, Da Silva H, Florence AT. (1990). A procedure for the efficient entrapment of drugs in dehydration-rehydration liposomes. Int J Pharm, 65(3): 235-242.
35. Gu FX, Karnik R, Wang AZ, et al. (2007). Targeted nanoparticles for cancer therapy. Nano Today, 2(3): 14-21.
36. Harivardhan Reddy L, Ramachandra Murthy R. (2004). Influence of polymerization technique and experimental variables on the particle properties and release kinetics of methotrexate from poly(butylcyanoacrylate) nanoparticles. Acta Pharm, 54(2): 103-118.
37. Hathout RM, Mansour S, Mortada ND, Guinedi AS. (2007). Liposomes as an ocular delivery system for acetazolamide: in vitro and in vivo studies. AAPS PharmSciTech, 8: Article 1. 10.1208/pt0801001.
38. Hatziantoniou S, Nezis IP, Margaritis LH, Demetzos C. (2007). Visualisation of liposomes prepared from skin and stratum corneum lipids by transmission electron microscopy. Micron, 38: 777-781. 10.1016/j.micron.2007.06. 005. (Pubitemid 47539892)
39. Hoet PH, Brüske-Hohlfeld I, Salata OV. (2004). Nanoparticles-known and unknown health risks. J Nanobiotechnol, 2: 12-17.
40. Honeywell-Nguyen PL, Bouwstra JA. (2005). Vesicles as a tool for transdermal and dermal delivery. Drug Discov Today: Tech, 2(1): 67-74.
41. Krauze MT, Mcknight TR, Yamashita Y, Bringas J, Noble CO, Saito R, Geletneky K, Forsayeth J, Berger MS, Jackson P, Park JW, Bankiewicz KS. (2005). Real-time visualization and characterization of liposomal delivery into the monkey brain by magnetic resonance imaging. Brain Res Brain Res Protoc, 16: 20-26. 10.1016/j. brainresprot.2005.08.003. (Pubitemid 41774067)
42. Kreuter J. (2005). Application of nanoparticles for the delivery of drugs to the brain. Int. Congr Ser, 1277: 85-94.
43. Kreuter J, Alyautdin RN, Kharkevich DA, Ivanov AA. (1995). Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Res, 674: 171-174.
44. Kulkarni P, Roney C, Arora V, Bennett M, Russell D, Fuchs P, White C. (2007). Imaging plaques in animal models of AD using nanoparticles encapsulated with radioiodinated clioquinol. J Nucl Med, 48(Suppl 2): 130.
45. Lamprecht A, Schäfer U, Lehr CM. (2000). Structural analysis of microparticles by confocal laser scanning microscopy. AAPS PharmSciTech, 1(3): article 17.
46. Landfester K. (2001). The generation of nanoparticles in miniemulsions. Adv Mater, 13: 765-768.
47. Lasic DD. (1997). Liposomes in Gene Delivery (p. 295). CRC Press: Boca Raton.
48. Lee PW, Peng SF, Su CJ, Mi FL, Chen HL, Wei MC, Lin HJ, Sung HW. (2008). The use of biodegradable polymeric nanoparticles in combination with a low-pressure gene gun for transdermal DNA delivery. Biomaterials, 29: 742-751. 10.1016/j. biomaterials.2007.10.034.
49. Liang HF, Yang TF, Huang CT, Chen MC, Sung HW. (2005). Preparation of nanoparticles composed of poly(gamma-glutamic acid)-poly(lactide) block copolymers and evaluation of their uptake by HepG2 cells. J Control Release, 105: 213-225.
50. Lieberman AN, Goldstein M. (1985). Bromocriptine in Parkinson disease. Pharmacol Rev, 37: 217-227.
51. Liu G, Garrett MR, Men P, Zhu X, Perry G, Smith MA. (2005). Nanoparticle and other metal chelation therapeutics in Alzheimer disease. Biochim Biophys Acta, 1741(3): 246-252. 10.1016/j.bbadis.2005.06.006. (Pubitemid 41338670)
52. Maestrelli F, González-Rodríguez ML, Rabasco AM, Mura P. (2006). Effect of preparation technique on the properties of liposomes encapsulating ketoprofen-cyclodextrin complexes aimed for transdermal delivery. Int J Pharm, 312: 53-60. 10.1016/j. ijpharm.2005.12.047.
53. Mao SR, Wang YZ, Ji HY, Bi DZ. (2003). Preparation of solid lipid nanoparticles by microemulsion technique. Acta Pharm Sinica, 38(8): 624-626.
54. Miguel V, Balbi D, Castillo C, Villegas R. (1992). Reconstitution of sodium channels in large liposomes formed by the addition of acidic phospholipids and freeze-thaw sonication. J Membr Biol, 129: 37-47.
55. Mozafari MR. Nanocarrier Technologies: Frontiers of Nanotherapy.
56. SpringerMüller RH, Mäder K, Gohla S. (2000). Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur J Pharm Biopharm, 50: 161-177.
57. Müller K, Klapper M, Müllen K. (2007). Polyester nanoparticles by non-aqueous emulsion polycondensation. J Polym Sci Part A: Polymer Chem, 45(6): 1101-1108.
58. Nagarwal RC, Kant S, Singh PN, Maiti P, Pandit JK. (2009). Polymeric nanoparticulate system: a potential approach for ocular drug delivery. J Control Release, 136: 2-13. 10.1016/j. jconrel.2008.12.018.
59. Papadimitriou S, Bikiaris D, Avgoustakis K, Karavas E, Georgarakis M. (2008). Chitosan nanoparticles loaded with dorzolamide and pramipexole. Carbohydr Polym, 73(1): 44-54.
60. Pardridge WM. (1999). Blood-brain barrier biology and methodology. J Neurovirol, 5: 556-569.
61. Pardridge WM. (2002). Drug and gene delivery to the brain: the vascular route. Neuron, 36: 555-558.
62. Priano L, Esposti D, Esposti R, Castagna G, De Medici C, Fraschini F, Gasco MR, Mauro A. (2007). Solid lipid nanoparticles incorporating melatonin as new model for sustained oral and transdermal delivery systems. J Nanosci Nanotechnol, 7: 3596-3601.
63. Rathod S, Deshpande SG. (2008). Albumin microspheres as an ocular delivery system for pilocarpine nitrate. Indian J Pharm Sci, 70(2): 193-197.
64. Reimold I, Domke D, Bender J, Seyfried CA, Radunz HE, Fricker G. (2008). Delivery of nanoparticles to the brain detected by fluorescence microscopy. Eur J Pharm Biopharm, 70: 627-632. 10.1016/j. ejpb.2008.05.007.
65. Sakai T, Kohno H, Ishihara T, Higaki M, Saito S, Matsushima M, Mizushima Y, Kitahara K. (2006). Treatment of experimental autoimmune uveoretinitis with poly(lactic acid) nanoparticles encapsulating betamethasone phosphate. Exp Eye Res, 82: 657-663. 10.1016/j.exer.2005.09.003. (Pubitemid 43122096)
66. Schäfer-Korting M, Mehnert W, Korting HC. (2007). Lipid nanoparticles for improved topical application of drugs for skin diseases. Adv Drug Deliv Rev, 59: 427-443. 10.1016/j.addr.2007.04.006. (Pubitemid 47259224)
67. Schnyder A, Huwyler J. (2005). Drug transport to brain with targeted liposomes. J Amer Soc Exp NeuroTherap, 2(1): 99-107.
68. Shenoy DB, Amiji MM. (2005). Poly(ethylene oxide)-modified poly(epsilon-caprolactone) nanoparticles for targeted delivery of tamoxifen in breast cancer. Int J Pharm, 293: 261-270.
69. Shim J, Seok Kang H, Park WS, Han SH, Kim J, Chang IS. (2004). Transdermal delivery of mixnoxidil with block copolymer nanoparticles. J Control Release, 97: 477-484.
70. Silva GA. (2008). Nanotechnology approaches to crossing the bloodbrain barrier and drug delivery to the CNS. BMC Neurosci, 9(Suppl 3): S4. 10.1186/1471-2202-9-S3-S4.
71. Sinico C, Manconi M, Peppi M, Lai F, Valenti D, Fadda AM. (2005). Liposomes as carriers for dermal delivery of tretinoin: in vitro evaluation of drug permeation and vesicle-skin interaction. J Control Release, 103: 123-136. 10.1016/j.jconrel.2004.11.020. (Pubitemid 40248567)
72. Soni V, Kohli DV, Jain SK. (2005). Transferrin coupled liposomes as drug delivery carriers for brain targeting of 5-florouracil. J Drug Target, 13: 245-250. 10.1080/10611860500107401. (Pubitemid 41086289)
73. Steiniger SC, Kreuter J, Khalansky AS, Skidan IN, Bobruskin AI, Smirnova ZS, Severin SE, Uhl R, Kock M, Geiger KD, Gelperina SE. (2004). Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. Int J Cancer, 109: 759-767. 10.1002/ ijc.20048.
74. Verma AML, Misra U, Mishra N, Bhardwaj P. (2009). Liposomes as carrier systems. InPharm Communique 2(2): 20-24.
75. Verma DD, Verma S, Blume G, Fahr A. (2003). Liposomes increase skin penetration of entrapped and non-entrapped hydrophilic substances into human skin: a skin penetration and confocal laser scanning microscopy study. Eur J Pharm Biopharm, 55: 271-277.
76. Visser CC, Stevanovic S, Voorwinden LH, van Bloois L, Gaillard PJ, Danhof M, Crommelin DJ, de Boer AG. (2005). Targeting liposomes with protein drugs to the blood-brain barrier in vitro. Eur J Pharm Sci, 25: 299-305. 10.1016/j.ejps.2005.03.008. (Pubitemid 40725060)
77. Walters KA. (2002). Dermatological and Transdermal Formulations (Drugs and the Pharmaceutical Sciences), Vol.119. Informa Health Care.
78. Xiang QY, Wang MT, Chen F, Gong T, Jian YL, Zhang ZR, Huang Y. (2007). Lung-targeting delivery of dexamethasone acetate loaded solid lipid nanoparticles. Arch Pharm Res, 30: 519-525.
79. Yasukawa T, Ogura Y, Tabata Y, Kimura H, Wiedemann P, Honda Y. (2004). Drug delivery systems for vitreoretinal diseases. Prog Retin Eye Res, 23: 253-281. 10.1016/j.preteyeres.2004.02.003. (Pubitemid 38737129)
80. Young TJ, Johnson KP, Pace GW, Mishra AK. (2004). Phospholipidstabilized nanoparticles of cyclosporine A by rapid expansion from supercritical to aqueous solution. AAPS PharmSciTech, 5(1): E11. 10.1208/pt050111.
81. Yuan H, Miao J, Du YZ, You J, Hu FQ, Zeng S. (2008). Cellular uptake of solid lipid nanoparticles and cytotoxicity of encapsulated paclitaxel in A549 cancer cells. Int J Pharm, 348: 137-145. 10.1016/j. ijpharm.2007.07.012.
82. Zhang N, Ping QN, Huang GH, Xu WF. (2005). Investigation of lectinmodified insulin liposomes as carriers for oral administration. Int J Pharm, 294: 247-259. 10.1016/j.ijpharm.2005.01.018. (Pubitemid 40462339)
83. Zhang Y, Wang Y, Boado RJ, Pardridge WM. (2008). Lysosomal enzyme replacement of the brain with intravenous non-viral gene transfer. Pharm Res, 25: 400-406. 10.1007/s11095-007-9357-9366
84. Zhu J, Xue J, Guo Z, Marchant RE. (2007). Vesicle size and stability of biomimetic liposomes from 3?-sulfo-Lewis a (SuLea) containing glycolipids. Colloids Surf B Biointerfaces, 58: 242-249. 10.1016/j. colsurfb.2007.03.016.